AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Abbreviated New Drug Application (ANDA) disputes regarding Injectafer® (ferric carboxymaltose) have now been settled St. Gallen, Switzerland, and...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Focus on expansion in nephrology, and to maximize opportunities on the iron portfolio Vifor Pharma to divest non-core assets on finished drug product...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR St. Gallen, Switzerland, 13 December 2021 – Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR St. Gallen, Switzerland, and Uniondale, NY,– 10 December 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from...